Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Jacqueline Lehmann-Che1, Brigitte Poirot1, Jean Christophe Boyer2

  • 1Laboratoire d'oncologie moléculaire, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75475 Paris, France; Unité CNRS UMR7212/U944, équipe de recherche translationnelle en oncologie, bâtiment Jean-Bernard, 75475 Paris, France.

Therapie
|February 7, 2017
PubMed
Summary

No abstract available in PubMed .

Keywords:
Biomarqueurs théranostiquesMédecine personnaliséeThérapie ciblée

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Breast Cancer Diagnosis and HER2+ Versus Triple Negative Discrimination by Infrared Spectral Histopathology.

Analytical chemistry·2026
Same author

Spatial transcriptomics unveils immune cellular ecosystems associated with patient survival in diffuse large B-cell lymphoma.

Oncoimmunology·2026
Same author

Preserved IDH mutation and methylation class in vorasidenib nonresponders: A report of 2 cases.

Neuro-oncology practice·2026
Same author

Molecular convergence of luminal androgen receptor and molecular apocrine defines a distinct entity in ER-negative breast tumors.

Breast cancer research : BCR·2025
Same author

Genetic polymorphisms of <i>VEGFR2</i> and <i>FGFR2</i> genes are associated with exposure to sunitinib and cardiovascular toxicity.

Pharmacogenomics·2025
Same author

Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AML.

HemaSphere·2025